Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00076635 · ClinicalTrials.gov registry record · Phase 3
An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF
A Phase 3 study, sponsored by InterMune.
- Terminated
- Registry status
- Phase 3
- Development phase
- 91
- Enrollment target
NCT00076635 is a Phase 3 study that was terminated before completion, run by InterMune. The registered enrollment target is 91 participants.
The verdict
NCT00076635, a Phase 3 study, was terminated before completion, sponsored by InterMune.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 91 participants
- Enrollment target
Study Summary
Open-label therapy will be administered to up to 220 patients, following completion of either InterMune Protocol GIPF-002 Part B or Protocol GIPF-004, to assess the long-term safety of subcutaneous Interferon gamma-1b. The study duration will be 5 years.
Interventions
- DRUG Interferon gamma-1b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2003-11 |
| Est. Completion | 2007-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00076635
The ClinicalTrials.gov registry entry for NCT00076635 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InterMune, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interferon gamma-1b is the first listed.
NCT00076635 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00076635 about?
NCT00076635 is a clinical study titled "An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF". Open-label therapy will be administered to up to 220 patients, following completion of either InterMune Protocol GIPF-002 Part B or Protocol GIPF-004, to assess the long-term safety of subcutaneous Interferon gamma-1b. The study duration will be 5 years.
What is the current status of trial NCT00076635?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 91 participants. The study started on 2003-11. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00076635?
The interventions under investigation include: Interferon gamma-1b (DRUG).
Who is sponsoring clinical trial NCT00076635?
This trial is sponsored by InterMune, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.